Tauroursodeoxycholic acid

Basic Information


CAS ID: 14605-22-2
Molecular Formula: C26H45NO5S
Molecular Weight: 483.7 g/mol
Monoisotopic Mass: 483.3018 g/mol
Class: Small Molecule
Natural Product: No
Other Names: Taurolithocholate | Tauroursodeoxycholic acid
Analysis: Drug repositioning mechanism analysis

O NH S O O OH OH


Compound Structure and Identifier


InChI: InChI=1S/C26H45NO5S/c1-17(4-9-24(29)27-14-15-33(30,31)32)21-7-8-22-20-6-5-18-16-19(28)10-12-25(18,2)23(20)11-13-26(21,22)3/h17-23,28H,4-16H2,1-3H3,(H,27,29)(H,30,31,32)/t17-,18-,19-,20+,21-,22+,23+,25+,26-/m1/s1 See All
InChI Key: QBYUNVOYXHFVKC-GBURMNQMSA-N
Smiles: C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C See All
Molfile: Download


Related Target



Related Fibrosis Property


Reference Record 1

PubMed ID 28883502 Target ID
Uniprot ID Name
Model human,mice Fibrosis Disease Ovarian fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Reference Record 2

PubMed ID 21274875 Target ID
Uniprot ID Name
Model vitro,rat Fibrosis Disease Liver fibrosis
Process I attenue inflammation
Process II cells proliferation
Process III prevenet collagen deposition
Mechanism

Reference Record 3

PubMed ID 21410058 Target ID
Uniprot ID Name
Model rat Fibrosis Disease Liver fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID NCT02937012 Disease Liver fibrosis
Phase Phase 3 Status Recruiting
First Received October 18, 2016 Last Verified April 23, 2018
Sponsor Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Trial Record 2

ClinicalTrial ID NCT01857284 Disease Liver fibrosis
Phase Phase 3 Status Completed
First Received May 20, 2013 Last Verified May 20, 2013
Sponsor Beijing Friendship Hospital

Related Link


PubChem: 439763
ChEMBL: CHEMBL408701